1. Hiremath S, Velez JC. Curr Opin Nephrol Hypertens 2020; 29(1):152-60.
  2. Christiansen C. Toxicology 2005; 209(2): 185-7.
  3. Almén T. Acta Radiol 1995; 36(Suppl.399): 2-18.
  4. Widmark JM. Proc (Bayl Univ Med Cent) 2007; 20(4): 408-17.
  5. Keuffel E et al. J Med Econ 2017; 21(4): 356-64.
  6. Luo S, Grams ME. Kidney Int 2020; 97(3): 477-86.
  7. Saeedi P et al. Diabetes Res Clin Pract; 157: 107843.
  8. Wild CP et al. Presented at the World Cancer Congress, Kuala Lumpur, Malaysia, October 2018.
  9. United Nations. World Population Prospects 2019: Highlights, June 2019.
  10.  Fountaine H et al. Acad Radiol 1996; 3(Suppl.3): S475-84.
  11. Ronco F et al. Rev Cardiovasc Med 2020; 21(1): 9-23. 

Prepared for your procedure

  1. Kinnaird T et al. Am Heart J 2020; 222: 15-25.
  2. Riley RF. J Am Coll Cardiol 2020; 75(8): 980-84.
  3. Kirtane AJ et al. Circulation 2016; 134(5): 422-31.
  4. Werner N et al. Clin Res Cardiol 2018; 107(Suppl.2): 64-73.
  5. De Marzo V et al.Minerva Cardioangiol 2018; 66(5): 576-93.
  6. Mehran R et al. N Engl J Med 2019; 380(22): 2146-55.
  7. Pavlidis AN. Am J Cardiol 2015; 115(6): 844-51.
  8. Azzalini L et al. Can J Cardiol 2016; 32(2): 247-55.
  9. Keuffel E et al. J Med Econ 2017; 21(4): 356-364.
  10. Almendarez M et al. JACC Cardiovasc Interv 2019; 12(19): 1877-88.
  11. Chawla LS et al. Clin J Am Soc Nephrol 2014; 9(3): 448-56.
  12.  McCullough PA et al. J Comp Eff Res 2018; 7(4): 331-41.
  13. McCullough P. Cardiorenal Med 2011; 1(4): 220-34.
  14. Dong M et al. J Nephrol 2012; 25(3): 290-301.
  15. Prasad A et al. Catheter Cardiovasc Interv 2017; 89(3): 383-92.
  1. McCullough PA, Capasso P. BMC Med Imaging 2011; 11: 12.
  2. Palena LM et al. Catheter Cardiovasc Interv 2014; 84(6): 1019–25.
  3. ESC/ESO et al. Eur Heart J 2011; 32(22): 2851-906.
  4. VSGBI. The Provision of Services for Patients with Vascular Disease 2015.
  5. Katsanos K et al. Clin Interv Aging 2009; 4: 1-15.
  6. Gupta RK, Bang TJ. Semin Intervent Radiol 2010; 27(4): 348-59.
  7. Cicin I et al. Eur Radiol 2014; 24(1): 184-90.
  8. Hiremath S, Velez JC. Curr Opin Nephrol Hypertens 2020; 29(1):152-60.
  9. Keuffel E et al. J Med Econ 2017; 21(4): 356-64.
  10. Prasad A et al. Presented at the TCT Conference, San Francisco, USA, September 2019.
  11.  Amin A et al. Presented at the TCT Conference, San Francisco, USA, September 2019.
  12. McCullough P. Cardiorenal Med 2011; 1(4): 220-34.
  13. Dong M et al. J Nephrol 2012; 25(3): 290-301. 
    AKI: acute kidney injury
    AMI: acute myocardial infarction
    CKD: chronic kidney disease
    CLI: critical limb ischemia
    CI-AKI: contrast-induced acute kidney injury
    CM: contrast media
    ESC: European Society of Cardiology
    ESO: European Stroke Organisation
    EVAR: endovascular abdominal aortic aneurysm repair
    MARCE: major adverse renal and cardiovascular events (defined as AKI with or without dialysis, acute renal failure with dialysis, CI-AKI, AMI, stent occlusion/ thrombosis, stroke, TIA or death)
    PAD: peripheral artery disease
    RCT: randomised controlled trials
    TCT: Transcatheter Cardiovascular Therapeutics
    TIA: transient ischemic attack

    VSGBI: Vascular Society of Great Britain & Ireland
  1. Sharma B et al. Nat Rev Clin Oncol 2012; 9: 728–37.
  2. Cosmai L et al. ESMO Open 2020; 5(2): e000618.
  3. Hong S-I et al. Support Care Cancer 2016; 24(3): 1011-7.
  4. Salahudeen AK et al. Clin J Am Soc Nephrol 2013; 8(3): 347-54.
  5. Cicin I et al. Eur Radiol 2014; 24(1): 184-90.

    AKI: acute kidney injury
    CI: confidence interval
    CM: contrast media
    CT: computed tomography
    PC-AKI: post-contrast AKI 

News and Articles

Prescribing Information

Please refer to full national Summary of Product Characteristics (SPC) before prescribing.
Indications and approvals may vary in different countries. Further information available on request.

An isotonic, aqueous solution containing iodixanol, a non-ionic, dimeric contrast medium, available in two strengths containing either 270 mg or 320 mg iodine per ml.

For diagnostic use only X-ray contrast medium for use in adults in cardioangiography, cerebral angiography (conventional), peripheral arteriography (conventional), abdominal angiography (i.a. DSA), urography, venography, CT enhancement, studies of the upper gastrointestinal tract, arthrography and hysterosalpingography (HSG) Lumbar, thoracic and cervical myelography in adults. In children for cardioangiography, urography, CT enhancement and studies of the upper gastrointestinal tract.

Adults and children: Dosage varies depending on the type of examination, age, weight, cardiac output, general condition of patient and the technique used (see SPC and package leaflet). For correct use of 500 mL multi-dose bottles, refer to full SPC. Multi-dose bottles must be used within 24 hours of opening.

Manifest thyrotoxicosis. Hypersensitivity to the active substance or to any of the excipients.

A positive history of allergy, asthma, or reaction to iodinated contrast media indicates need for special caution. Premedication with corticosteroids or H1 and H2 antagonists might be considered in these cases. Although the risk of serious reactions with VISIPAQUE is regarded as remote, iodinated contrast media may provoke serious life-threatening hypersensitivity reactions, including fatal anaphylactic reactions. Therefore the necessary drugs and equipment must be available for immediate treatment. Patients should be observed closely for at least 30 minutes following administration of contrast medium, however delayed reactions may occur. Use of beta blockers may be a risk factor for anaphylactoid reactions and patients may present with atypical symptoms of hypersensitivity which may be misinterpreted as a vagal response.
Non-ionic iodinated contrast media inhibit blood coagulation in vitro, less than ionic contrast media. When performing vascular catheterisation procedures one should pay meticulous attention to the angiographic technique and flush the catheter frequently (e.g. with heparinised saline) so as to minimize the risk of procedure-related thrombosis and embolism. Serious, rarely fatal, thromboembolic events causing, myocardial infarction and stroke have been reported during angio-cardiographic procedures with both ionic and non-ionic contrast media. Advanced life support facilities should be readily available. There is a risk of thromboembolism in patients with homocystinuria. Ensure adequate hydration before and after examination especially in patients with multiple myeloma, renal dysfunction, diabetes mellitus, paraproteinemias, the elderly, children and infants. Care should be taken in patients with serious cardiac disease and pulmonary hypertension as they may develop hemodynamic changes or arrhythmias. In intravascular application, care should be taken in patients with acute stroke, or acute intracranial bleeding, in patients with altered blood brain barrier, cerebral oedema or acute demyelinisation. Particular care is required in patients with severe disturbance of both renal and hepatic function as they may have significantly delayed contrast medium clearance. For haemodialysis patients, correlation of time of contrast media injection with the haemodialysis session is unnecessary. To prevent lactic acidosis in diabetic patients treated with metformin, administration of metformin should be discontinued at the time of administration of contrast medium and withheld for 48 hours and reinstituted only after renal function has been re-evaluated and found to be normal. (Refer to SPC). Special care should also be taken in patients with hyperthyroidism, serious cardiac disease, pulmonary hypertension, arteriosclerosis, patients predisposed to seizures (acute cerebral pathology, tumours, epilepsy, alcoholics and drug addicts), and patients with myasthenia gravis or phaeochromocytoma. One should also be aware of the possibility of inducing transient hypothyroidism in premature infants receiving contrast media. After intrathecal use the patient should rest with head and thorax elevated for one hour and outpatients should not be alone for 24 hours.
All iodinated contrast media may interfere with laboratory tests for thyroid function, bilirubin, proteins, or inorganic substances (e.g. iron, copper, calcium, and phosphate). An increased risk of delayed reactions (flu-like or skin reactions) has been associated with patients treated with interleukin-2 up to two weeks previously.

The safety of VISIPAQUE in pregnancy has not been established. Contrast media are poorly excreted in breast milk and minimal amounts are absorbed by the intestine. Breast feeding may be continued normally. Thyroid function should be checked in neonates during the first week of life, following administration of iodinated contrast agents to the mother during pregnancy and repeat testing of thyroid function is recommended at 2 to 6 weeks of age, particularly in low birth weight newborn or premature newborn.

It is not advisable to drive or use machines for one hour after injection or for 24 hours after intrathecal procedure.

Undesirable effects are usually mild to moderate, and transient in nature. Serious reactions and fatalities are only seen on very rare occasions. Serious reactions as well as fatalities are only seen on very rare occasions, these may include acute or chronic renal failure, anaphylactic or anaphylactoid shock, hypersensitivity reaction followed by cardiac reactions (Kounis’ syndrome), cardiac or cardio-respiratory arrest and myocardial infarction. Hypersensitivity may present as respiratory or cutaneous symptoms like dyspnoea, rash, erythema, urticaria, pruritus, skin reactions, angioneurotic oedema, hypotension, fever, laryngeal oedema, bronchospasm or pulmonary oedema. In patients with autoimmune diseases cases of vasculitis and SJS-like syndrome were observed. They may occur immediately after injection or up to a few days later, irrespective of dose, and mild symptoms may be the first signs of serious anaphylactoid reaction/shock. Intravascular use: Uncommon: hypersensitivity, headache, flushing, nausea, vomiting, rash, pruritus, urticaria, feeling hot, chest pain. Rare: dizziness, arrhythmia (including bradycardia, tachycardia), myocardial infarction, hypotension, cough, pain, discomfort, shivering (chills), pyrexia, administration site reactions including extravasation. Very rare: agitation, anxiety, cerebrovascular accident, sensory abnormalities including taste, amnesia, paraesthesia, syncope, cardiac arrest, transient cortical blindness, visual impairment, hypertension, ischaemia, dyspnoea, abdominal pain/discomfort, angioedema, erythema, back pain, muscle spasm, impairment of renal function including acute renal failure, feeling cold, asthenic conditions (e.g. malaise, fatigue). Frequency unknown: thrombocytopenia, anaphylactoid reaction, anaphylactoid shock, confusional state, coma, motor dysfunction, disturbances in consciousness, convulsion, transient contrast-induced encephalopathy (including hallucination), tremor, cardiac failure, ventricular hypokinesia, myocardial ischaemia, cardio-respiratory arrest, conduction abnormalities, coronary artery thrombosis, angina pectoris, arterial spasm, thrombosis, thrombophlebitis, shock, pulmonary oedema, respiratory arrest, respiratory failure, acute or aggravated pancreatitis, salivary gland enlargement, bullous dermatitis, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, acute generalised exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms, drug eruption, dermatitis allergic, skin exfoliation, arthralgia, iodism. Intrathecal use: Uncommon: headache (may be severe and lasting), vomiting. Frequency unknown: hypersensitivity including anaphylactic/anaphylactoid reactions, dizziness, transient contrast-induced encephalopathy including amnesia, hallucination, confusion, nausea, muscle spasm, shivering, pain at injection site.
Hysterosalpingography: Very common: abdominal pain, vaginal haemorrhage. Common: headache, nausea, pyrexia. Frequency unknown: hypersensitivity, vomiting, shivering, injection site reaction.
Arthrography: Common: injection site pain. Frequency unknown: hypersensitivity including anaphylactic/anaphylactoid reactions, shivering.
GI tract: Common: diarrhoea, abdominal pain, nausea. Uncommon: vomiting. Frequency unknown: hypersensitivity including anaphylactic/anaphylactoid reactions, shivering.

In the event of accidental overdosing, the water and electrolyte losses must be compensated by infusion. Renal function should be monitored for at least the next 3 days. If needed, haemodialysis may be used to remove iodixanol from the patient's system. Treatment of overdose is symptomatic.

ATC code: V08A B09.
In 64 diabetic patients with serum creatinine levels of 115 - 308 µmol/L, VISIPAQUE use resulted in 3% of patients experiencing a rise in creatinine of ≥ 44.2 µmol/L and 0% of the patients with a rise of ≥ 88.4 µmol/L. The release of enzymes (alkaline phosphatase and N-acetyl-β-glucosaminidase) from the proximal tubular cells is less than after injections of non-ionic monomeric contrast media and the same trend is seen compared to ionic dimeric contrast media. VISIPAQUE is also well tolerated by the kidney.

Do not mix with other medicinal products. Like all parenteral products, VISIPAQUE should be inspected visually for particulate matter, discolouration and the integrity of the container prior to use. The product should be drawn into the syringe immediately before use. Containers are intended for single use only; any unused portions must be discarded. VISIPAQUE may be warmed to body temperature (37°C) before administration.

GE Healthcare AS, Nycoveien 1-2, Postboks 4220 Nydalen, N-0401 Oslo, Norway.

Subject to medical prescription (POM). MARKETING AUTHORISATION NUMBERS PL 0637/0018-19 (Glass vials/bottles and polypropylene bottles with stopper and screw cap).

April 2019

320mgI/ml, 10x50ml: £208.22

Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/
Adverse events should also be reported to GE Healthcare at